Global Blood Therapeutics, Inc. (NASDAQ:GBT) released its earnings results on Monday, August 7th. The company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.06, Briefing.com reports. During the same period in the prior year, the company posted ($0.58) EPS.
Shares of Global Blood Therapeutics (NASDAQ:GBT) remained flat at $27.60 during trading on Friday. 428,356 shares of the stock were exchanged. The stock’s market cap is $1.21 billion. The firm has a 50 day moving average price of $28.08 and a 200 day moving average price of $29.17. Global Blood Therapeutics has a 52-week low of $13.35 and a 52-week high of $41.15.
In other Global Blood Therapeutics news, Director Deval L. Patrick sold 27,053 shares of the stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $29.69, for a total transaction of $803,203.57. Following the completion of the sale, the director now owns 12,053 shares of the company’s stock, valued at approximately $357,853.57. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Jung Choi sold 3,000 shares of the stock in a transaction on Friday, July 21st. The shares were sold at an average price of $30.00, for a total transaction of $90,000.00. Following the sale, the insider now directly owns 143,255 shares of the company’s stock, valued at approximately $4,297,650. The disclosure for this sale can be found here. 5.30% of the stock is currently owned by corporate insiders.
Several analysts recently issued reports on GBT shares. Morgan Stanley reiterated an “overweight” rating on shares of Global Blood Therapeutics in a research report on Tuesday, July 11th. Wedbush reissued an “outperform” rating and set a $73.00 price objective on shares of Global Blood Therapeutics in a research note on Tuesday, May 2nd. BidaskClub lowered Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. Janney Montgomery Scott initiated coverage on Global Blood Therapeutics in a research note on Monday, May 1st. They set a “buy” rating and a $37.00 price objective for the company. Finally, ValuEngine cut Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, June 3rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and twelve have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $49.73.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
What are top analysts saying about Global Blood Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Global Blood Therapeutics Inc. and related companies.